We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


New Colon Cancer Classification System Aims To Guide Treatment and Clinical Trials

New Colon Cancer Classification System Aims To Guide Treatment and Clinical Trials content piece image
Human colon cancer cells with the cell nuclei stained red and the protein E-cadherin stained green. Credit: Urbain Weyemi, Christophe E. Redon, William M. Bonner/ NCI Center for Cancer Research
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 3 minutes

  • Colorectal cancer is the second deadliest cancer in Singapore and worldwide.
  • Classifying colorectal cancer patients into different subgroups is important to direct and optimise treatment and improve outcomes.
  • A multi-national team of clinicians and scientists have discovered a fundamental dichotomous grouping of colorectal cancer cells that proposes an update to the CMS classification system, that can impact drug development strategies and stratify treatment approaches for different subgroups of colorectal cancer patients.

A team of clinician-scientists and scientists, led by the National Cancer Centre Singapore (NCCS) and A*STAR’s Genome Institute of Singapore (GIS) together with collaborators in Europe and South Korea, used single cell techniques to uncover a central dichotomy for colorectal cancer cells, leading to a proposed update of the classification system for the disease. These findings, published in Nature Genetics on 30 June 2022, have implications for drug development and treatment approaches in colorectal cancer.

In Singapore and worldwide, colorectal cancer is one of the most common cancers and the second-leading cause of cancer death. As it is a heterogeneous disease with substantial biological and clinical differences amongst patients, treating colorectal cancer and prescribing individualised treatment for patients directed by the biology of their disease is a challenge. In 2015, clinicians and scientists classified colorectal cancer based on genes expressed by the tumour (transcriptomics) leading to the 2015 international consensus molecular subtype (CMS1-4) classification, that is to date, the most robust and widely used transcriptomic system. However, the CMS classification relied on transcriptomic analysis of the entire tumour which meant that the individual differences from cancer cells and other stromal cells (e.g. immune, fibroblast & blood vessel cells) were obscured and could not be distinguished.

“The current classification systems for colorectal cancer do not adequately highlight the molecular underpinnings of the disease,” said co-senior author Professor Shyam Prabhakar, Associate Director of Spatial and Single Cell Systems at GIS. “Our team examined the malignant (epithelial) cell subtypes and defined their properties to understand their interactions with other cells using single cell profiling, so that we could accurately describe the heterogeneity of colorectal cancer.”

The NCCS and GIS-led research team analysed 373,000 single cells from 141 tumour samples collected from 63 colorectal cancer patients in Singapore, Belgium and South Korea.  Using single-cell and bulk transcriptomics, the team found that the malignant cells belong to two major epithelial subtypes, that they have termed intrinsic-consensus molecular subtypes (iCMS), consisting of iCMS2 and iCMS3, uncovering a central dichotomy that cut across previous classifications of colorectal cancer. Each subtype is characterised by distinct molecular signalling cascades and patterns of DNA duplications or deletions, mutations in key genes, RNA abundance patterns and gene regulatory networks.

Colorectal cancer is widely classified by two systems, microsatellite instable (MSI-H) and microsatellite stable (MSS) colorectal cancer. Colorectal cancer with MSI-H is considered to be very responsive to immunotherapy while MSS cancers are refractory to immunotherapy. Drug development and clinical trials are ongoing to address this pressing unmet need of finding immunotherapies that can work to treat MSS colorectal cancers. However, these trials currently classify MSS colorectal cancer as one group.

The research team found that one-third of MSS tumours were iCMS3 subtype and had cancer cells much more similar to MSI cancers rather than other MSS cancers. Understanding the similarities between MSI-H cancers and iCMS3 MSS cancers could lead to an identification of components that can be exploited to adapt and modify immunotherapy regimens, that might work best in these patients with biology similar to MSI-H cancers. Conversely, understanding the distinct biology of iCMS2 MSS cancers could allow targeted drug development focused on this group of colorectal cancer. Furthermore, the CMS4 group of colorectal cancers, known to have the highest tendency to metastasise, was evenly divided into the iCMS2 and iCMS3 subtypes. Between these two groups, CMS4 cancers with iCMS3 epithelial cells were found to have the worst prognosis.

Based on their findings the research team proposed a refinement of the CMS classification known as “IMF”, which groups colorectal cancer into five groups based on their epithelial status, microsatellite status and the presence of fibrosis. The proposed IMF classification provides new insight into colorectal cancer and its origin, evolution and response to therapies. Further pre-clinical and clinical studies into the biology of the five groups could inform prevention, diagnosis and therapy.

“Currently, clinical trials focus on using immunotherapy combinations to treat microsatellite stable colorectal cancers as one group, not accounting for differences amongst microsatellite stable colorectal cancers. Our study changes the understanding of the diversity of colorectal cancer by showing that there are fundamentally different biological subsets with distinct epithelial characteristics, microsatellite status and interactions with fibrosis. This could help purposefully strategise drug development efforts to effectively target these different subsets of colorectal cancer,” said co-senior author Associate Professor Iain Tan, Senior Consultant and Director of Research, Division of Medical Oncology, NCCS.


The research team plans to perform further analyses to characterise the biological properties, interactions and drug response of iCMS2 and iCMS3 cells, and also re-analyse data from clinical trials to identify differences in treatment response between these two cancer types.

Reference: Joanito I, Wirapati P, Zhao N, et al. Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer. Nat Genet. 2022. doi: 10.1038/s41588-022-01100-4


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.